7.25
price up icon5.69%   0.39
after-market Handel nachbörslich: 7.24 -0.010 -0.14%
loading
Schlusskurs vom Vortag:
$6.86
Offen:
$6.97
24-Stunden-Volumen:
28,314
Relative Volume:
0.14
Marktkapitalisierung:
$42.48M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.2814
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
+5.07%
1M Leistung:
-15.60%
6M Leistung:
-25.41%
1J Leistung:
-53.97%
1-Tages-Spanne:
Value
$6.6701
$7.25
1-Wochen-Bereich:
Value
$5.94
$7.25
52-Wochen-Spanne:
Value
$5.40
$20.81

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Name
Firmenname
Atara Biotherapeutics Inc
Name
Telefon
805-623-4211
Name
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Name
Mitarbeiter
153
Name
Twitter
@Atarabio
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ATRA's Discussions on Twitter

Vergleichen Sie ATRA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATRA
Atara Biotherapeutics Inc
7.25 42.48M 100.44M -133.16M -94.85M -25.76
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
504.77 129.62B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
666.87 72.91B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
604.96 36.76B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.76 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
259.19 27.86B 3.32B -860.46M -1.04B -8.32

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-09 Herabstufung Evercore ISI Outperform → In-line
2023-11-09 Herabstufung H.C. Wainwright Buy → Neutral
2023-11-09 Herabstufung Mizuho Buy → Neutral
2022-07-20 Herabstufung Citigroup Neutral → Sell
2022-07-13 Herabstufung JP Morgan Overweight → Neutral
2022-07-13 Herabstufung Stifel Buy → Hold
2022-05-10 Herabstufung Citigroup Buy → Neutral
2021-05-13 Hochstufung JP Morgan Neutral → Overweight
2020-12-09 Herabstufung Citigroup Buy → Neutral
2020-12-08 Bestätigt H.C. Wainwright Buy
2020-11-10 Bestätigt H.C. Wainwright Buy
2020-06-30 Eingeleitet Evercore ISI Outperform
2020-06-15 Eingeleitet H.C. Wainwright Buy
2020-04-23 Hochstufung Citigroup Neutral → Buy
2019-11-08 Herabstufung JP Morgan Overweight → Neutral
2019-09-27 Herabstufung Goldman Neutral → Sell
2019-09-16 Herabstufung Jefferies Buy → Hold
2019-06-04 Hochstufung Citigroup Sell → Neutral
2019-05-30 Eingeleitet ROTH Capital Buy
2019-05-23 Eingeleitet Stifel Buy
2019-01-23 Eingeleitet Mizuho Buy
2018-04-10 Eingeleitet JP Morgan Overweight
2018-03-16 Eingeleitet Guggenheim Neutral
2018-03-05 Bestätigt Jefferies Buy
2018-02-28 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2018-02-15 Herabstufung Citigroup Neutral → Sell
2018-01-03 Hochstufung Citigroup Sell → Neutral
2017-10-06 Fortgesetzt Goldman Neutral
Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

pulisher
Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025
pulisher
Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian

Mar 10, 2025
pulisher
Mar 09, 2025

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks

Mar 09, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Reports 2024 Financial Results - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics Inc. (ATRA) reports earnings - Quartz

Mar 07, 2025
pulisher
Mar 07, 2025

Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace

Mar 07, 2025
pulisher
Mar 07, 2025

Atara Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St

Mar 07, 2025
pulisher
Mar 06, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia

Mar 06, 2025
pulisher
Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia

Mar 06, 2025
pulisher
Mar 05, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 03, 2025

Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com

Mar 03, 2025
pulisher
Feb 27, 2025

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN

Feb 27, 2025
pulisher
Feb 26, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Feb 26, 2025
pulisher
Feb 21, 2025

(ATRA) Investment Analysis - Stock Traders Daily

Feb 21, 2025
pulisher
Feb 14, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen

Feb 14, 2025
pulisher
Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025
pulisher
Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal

Feb 11, 2025
pulisher
Feb 11, 2025

How the (ATRA) price action is used to our Advantage - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025
pulisher
Feb 10, 2025

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 10, 2025
pulisher
Feb 10, 2025

2025-02-10 | Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing

Feb 10, 2025
pulisher
Feb 09, 2025

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace

Feb 09, 2025
pulisher
Feb 09, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Markets Insider

Feb 09, 2025
pulisher
Feb 09, 2025

2025-02-09 | Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation | NDAQ:ATRA | Press Release - Stockhouse Publishing

Feb 09, 2025
pulisher
Feb 08, 2025

Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Brokerages - Armenian Reporter

Feb 08, 2025
pulisher
Feb 07, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Stock Quotes, Forecast and News Summary - Benzinga

Feb 07, 2025
pulisher
Feb 07, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect - Markets Insider

Feb 07, 2025
pulisher
Feb 06, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect - Markets Insider

Feb 06, 2025
pulisher
Feb 05, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation - Markets Insider

Feb 05, 2025
pulisher
Feb 04, 2025

Analysts Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Price Target at $17.75 - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation - Markets Insider

Feb 04, 2025
pulisher
Feb 04, 2025

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider

Feb 04, 2025
pulisher
Feb 03, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it - GlobeNewswire

Feb 03, 2025

Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$307.24
price up icon 0.61%
$76.55
price up icon 1.97%
$32.77
price up icon 0.28%
$20.79
price up icon 8.34%
$99.47
price up icon 2.06%
biotechnology ONC
$259.19
price up icon 1.81%
Kapitalisierung:     |  Volumen (24h):